{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=105", "query": { "intervention": "Protein Control", "page": 105 }, "page_size": 10 }, "pagination": { "page": 105, "page_size": 10, "total_count": 3500, "total_pages": 350, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=106&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=104&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T14:15:34.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01649297", "title": "A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "empagliflozin (low dose qd)", "type": "DRUG" }, { "name": "Empagliflozin (high dose qd)", "type": "DRUG" }, { "name": "empagliflozin (high dose bid)", "type": "DRUG" }, { "name": "empagliflozin (low dose bid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 983, "start_date": "2012-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-07-23", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 39, "location_summary": "Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more", "locations": [ { "city": "Florence", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649297" }, { "nct_id": "NCT07032649", "title": "Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HSV" ], "interventions": [ { "name": "Benzoyl Peroxide 10% Bar", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Greg Bew", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2026-01-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 1, "location_summary": "Evans, Georgia", "locations": [ { "city": "Evans", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07032649" }, { "nct_id": "NCT00100178", "title": "New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Mycophenolate mofeteil (MMF)", "type": "DRUG" }, { "name": "Daclizumab (DZB)", "type": "DRUG" }, { "name": "Placebo control for Mycophenolate mofeteil (MMF)", "type": "DRUG" }, { "name": "Placebo control for Daclizumab (DZB)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "8 Years to 45 Years" }, "enrollment_count": 126, "start_date": "2004-05", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100178" }, { "nct_id": "NCT03280550", "title": "A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nasal Polyps", "Chronic Rhinosinusitis" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 138, "start_date": "2017-11-15", "completion_date": "2019-03-11", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 11, "location_summary": "Los Angeles, California • Roseville, California • Miami, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Twin Falls", "state": "Idaho" }, { "city": "Marrero", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03280550" }, { "nct_id": "NCT01659658", "title": "Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Systemic Light Chain Amyloidosis" ], "interventions": [ { "name": "IXAZOMIB", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2012-12-26", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 15, "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01659658" }, { "nct_id": "NCT04639726", "title": "A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dietary Supplement" ], "interventions": [ { "name": "Whey Protein Micro Gel", "type": "DIETARY_SUPPLEMENT" }, { "name": "Water without Whey Protein.", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Société des Produits Nestlé (SPN)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-09-28", "completion_date": "2020-10-26", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 1, "location_summary": "Tustin, California", "locations": [ { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639726" }, { "nct_id": "NCT06074276", "title": "The Effects of Almond on Facial Skin Collagen and Wrinkles", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Collagen Degeneration", "Wrinkle", "Pigmentation", "Elastic Skin" ], "interventions": [ { "name": "Food: whole almonds", "type": "OTHER" }, { "name": "Food: non-nut snack", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Integrative Skin Science and Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "35 Years to 70 Years · Female only" }, "enrollment_count": 60, "start_date": "2023-10-04", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06074276" }, { "nct_id": "NCT00823940", "title": "A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK1362885", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Glucagon + GSK1362885", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2009-01-13", "completion_date": "2009-04-27", "has_results": false, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823940" }, { "nct_id": "NCT06425549", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque Psoriasis" ], "interventions": [ { "name": "bimekizumab", "type": "DRUG" }, { "name": "ustekinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 176, "start_date": "2024-06-25", "completion_date": "2030-11-08", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 7, "location_summary": "Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06425549" }, { "nct_id": "NCT00004255", "title": "Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Chimeric Therapies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-11-09T14:15:34.629Z", "location_count": 15, "location_summary": "La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004255" } ] }